Skip to main content

Table 4 Summary of cardiac PET findings in subjects with CS (N = 12*)

From: FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET

  FLT-PET FDG-PET p value
# of subjects with cardiac uptake (%) 6 (50%) 7 (58%) 0.70
# of LV segments involved ± SD 6.2 ± 1.5 7.3 ± 3.5 0.50
# of segments in LAD territory ± SD 2.5 ± 1.0 2.7 ± 1.3 0.75
# of segments in LCX territory ± SD 1.3 ± 1.0 1.7 ± 1.4 0.59
# of segments in RCA territory ± SD 2.5 ± 0.8 2.9 ± 1.5 0.61
# of subjects with RV uptake (%) 2 (17%) 4 (33%) 0.17
Maximum LV SUV ± SD 15.4 ± 4.4 13.7 ± 6.0 0.58
LV SUVTotal ± SD 27.7 ± 8.4 45.7 ± 33.1 0.22
Maximum RV SUV ± SD α 2.4 ± 0.4 4.6 ± 5.0 0.59
  Perfusion PET
# of subjects with perfusion defects (%) 10 (83%)
SRS ± SD 6.2 ± 4.6
SRS in LAD territory ± SD 3.2 ± 2.9
SRS in LCX territory ± SD 1.0 ± 1.3
SRS in RCA territory ± SD 2.0 ± 1.9
  1. LV left ventricle, RV right ventricle, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, SUV standardized uptake value
  2. *Only subjects satisfying the HRS criteria (N = 12/14) were included in this analysis
  3. Vascular territories defined as per AHA 17 segment model [13]
  4. αIncludes only those subjects with evidence of RV uptake